RNS REACH : 27 NOVEMBER 2025
ImmuPharma PLC
("ImmuPharma" or the "Company")
IMMUPHARMA ATTENDING BIO-EUROPE
3-5 November 2025, Vienna
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces that Tim McCarthy, CEO, Dr Tim Franklin, COO, and Dr Sebastien Goudreau, CSO will be attending the forthcoming Bio-Europe Conference in Vienna, from 3-5 November 2025.
BIO-Europe Vienna 2025, is the 31st annual premier biopharma partnering event. It brings together over 5,700 life science professionals from more than 3,000 companies across 60+ countries, facilitating more than 30,000 one-to-one meetings. This event makes it the leading life science partnering forum in Europe, fostering innovation, collaboration and growth in the biotech sector.
|
For further information please contact:
|
Notes to Editors
About ImmuPharma PLC
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives.
For additional information about ImmuPharma please visit www.immupharma.co.uk.
ImmuPharma's LEI (Legal Entity Identifier) code : 213800VZKGHXC7VUS895.
About Reach announcements
Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases such as marketing messages, corporate and product information into the public domain. An RNS Regulatory announcement is required to be notified under the AIM Rules for Companies.